Consynance Therapeutics
Manufacturing · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
11 University Pl Ste D210b, Rensselaer, ...Phone Number
(518) 275-0176Website
www.consynance.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Consynance Therapeutics
Consynance Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare central nervous system disorders, particularly Prader-Willi Syndrome. The company aims to address neuropsychiatric conditions related to neurotransmitter dysregulation, specifically targeting behavioral dysregulation and hyperphagia. Their lead product, CSTI-500, is a tunable triple monoamine reuptake inhibitor designed to meet the high unmet needs of patients. Consynance Therapeutics is dedicated to transforming scientific discoveries into life-changing treatments for affected individuals.Explore more
Consynance Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Consynance Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Consynance Therapeutics is spiking on competitors!
Click to see if Consynance Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Consynance Therapeutics has new funding data
Earning: See what the market has to say on Consynance Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Consynance Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Consynance Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Consynance Therapeutics launches new products
Consynance Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Consynance Therapeutics
Compare insights from companies similar to Consynance Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Consynance Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Consynance Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Consynance Therapeutics.
Consynance Therapeutics Tech Stack
A closer look at the technologies used by Consynance Therapeutics
Consynance Therapeutics News & Media
ConSynance Therapeutics Announces U.S. FDA Grants Rare Pediatric Disease Designation to CSTI-500, a Potential First-in-Class Therapy for Prader-Willi Syndrome
FDA awards ConSynance's CSTI-500 Rare Pediatric Disease Designation for innovative Prader-Willi Syndrome treatment.ConSynance Therapeutics Reports Positive Phase 1 Results for CSTI-500 in Prader-Willi Syndrome Patients
RENSSELAER, New York, May 30, 2023 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc., an emerging biopharmaceutical firm focused on developing novel therapies for rare central nervous system (CNS) disorders, today announced positive results from its Phase 1 trial for CSTI-500, a potential groundbreaking treatment for Prader-Willi Syndrome (PWS).Harmony Biosciences Acquires Asset With Novel Mechanism Of Action For The Potential Treatment Of Narcolepsy And Other Rare Neurological Diseases
PLYMOUTH MEETING, Pa., Aug. 9, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological diseases, today announced the acquisition...ConSynance Joins the Prader-Willi Syndrome Clinical Trial Consortium
Rensselaer, New York., March 11, 2019 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc., a clinical-stage biotechnology company developing two innovative treatments for Prader-Willi Syndrome (PWS), today announced that they joined the PWS Clinical Trial Consortium.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Consynance Therapeutics
Sign Up For FreeTo access detailed company insights
Consynance Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare central nervous system disorders, particularly Prader-Willi Syndrome. The company aims to address neuropsychiatric conditions related to neurotransmitter dysregulation, specifically targeting behavioral dysregulation and hyperph... Read More
